2,3,4,5,6-Pentakis-benzyloxy-cyclohexanol | 1214712-28-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2,3,4,5,6-Pentakis-benzyloxy-cyclohexanol
• 英文别名: 2,3,4,5,6-Pentakis(benzyloxy)cyclohexanol；2,3,4,5,6-pentakis(phenylmethoxy)cyclohexan-1-ol
• CAS: 1214712-28-3
• 化学式: C₄₁H₄₂O₆
• 分子量: 630.781
• InChiKey: PLKAJAVHVAUNLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.4
• 重原子数：
  47
• 可旋转键数：
  15
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.27
• 拓扑面积：
  66.4
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  2,3,4,5,6-Pentakis-benzyloxy-cyclohexanol 、 二乙胺基三氟化硫 、 三乙胺 、 四氢呋喃 以48%的产率得到
  参考文献：
  名称：

  LOWE, GORDON;MCPHEE, FIONA, J. CHEM. SOC. PERKIN TRANS. 1,(1991) N, C. 1249-1253

  摘要：

  DOI：
• 作为产物：
  描述：

  3,4,5,6-四(苄氧基)-1,2-环己二醇 生成 2,3,4,5,6-Pentakis-benzyloxy-cyclohexanol
  参考文献：
  名称：

  GAREGG, PER J.;LINDBERG, BEGNGT;KVARNSTROM, INGEMAR;SVENSSON, STEFAN C. T+, CARBOHYDR. RES., 173,(1988) N 2, 205-216

  摘要：

  DOI：

文献信息

• [EN] ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER<br/>[FR] PROMÉDICAMENTS ACÉTYLÉS POUR ADMINISTRATION À TRAVERS LA BARRIÈRE HÉMATO-ENCÉPHALIQUE
  申请人：MASSACHUSETTS GEN HOSPITAL

  公开号：WO2019204808A1

  公开（公告）日：2019-10-24

  The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the amino in the parent compound is presented as an amide in the compound, and their use to prevent or treat neurological disease.

  本公开涉及包括从具有羟基或氨基团的母化合物衍生的化合物的制药组合物，其中母化合物中的羟基在化合物中呈酯形式，或母化合物中的氨基在化合物中呈酰胺形式，并且它们的用途是预防或治疗神经系统疾病。
• Compounds and compositions for the detection and treatment of Alzheimer's disease and related disorders
  申请人：The General Hospital Corporation

  公开号：US10857247B2

  公开（公告）日：2020-12-08

  One aspect of the present invention relates to compounds, compositions and methods for diagnosis and/or treatment of a subject suffering from an amyloidosis-associated pathological condition. In certain embodiments, the imaging and/or therapeutic agents of the instant invention may be administered to a subject for identification and/or treatment of amyloid deposits. A specific imaging method detects amyloid deposits by administering the imaging agent to the subject and detecting the spatial distribution of the agent. Differential accumulation of the agent is indicative of AD or an amyloidosis-associated pathological condition and can be monitored by using a PET or SPECT camera.

  本发明的一个方面涉及用于诊断和/或治疗淀粉样变性相关病症的化合物、组合物和方法。在某些实施方案中，本发明的成像剂和/或治疗剂可用于受试者淀粉样蛋白沉积的鉴定和/或治疗。具体的成像方法是通过向受试者施用成像剂并检测成像剂的空间分布来检测淀粉样蛋白沉积。淀粉样蛋白沉积物的不同程度的积聚表明了多发性硬化症或与淀粉样蛋白沉积相关的病理状况，可使用 PET 或 SPECT 相机进行监测。
• RADIOTRACEUR NOTAMMENT POUR LE CANCER
  申请人：Université de Lorraine

  公开号：EP2847154B1

  公开（公告）日：2018-05-30
• COMPOUNDS AND COMPOSITIONS FOR THE DETECTION AND TREATMENT OF ALZHEIMER'S DISEASE AND RELATED DISORDERS
  申请人：The General Hospital Corporation

  公开号：EP3231804B1

  公开（公告）日：2021-03-03
• ACETYLATED PRODRUGS FOR DELIVERY ACROSS THE BLOOD-BRAIN BARRIER
  申请人：THE GENERAL HOSPITAL CORPORATION

  公开号：US20210238124A1

  公开（公告）日：2021-08-05

  The present disclosure relates to pharmaceutical compositions including a compound derived from a parent compound having a hydroxyl or amino moiety, wherein the hydroxyl in the parent compound is presented as an ester in the compound or the amino in the parent compound is presented as an amide in the compound, and their use to prevent or treat neurological disease.